AJR Join ARRS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Widder, D.
Right arrow Articles by Brady, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widder, D.
Right arrow Articles by Brady, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
American Journal of Roentgenology, Vol 148, Issue 2, 399-404
Copyright © 1987 by American Roentgen Ray Society


Articles

Magnetite albumin microspheres: a new MR contrast material

DJ Widder, WL Greif, KJ Widder, RR Edelman, and TJ Brady

A superparamagnetic MR contrast agent was synthesized by incorporating 150-250-A particles of magnetite (Fe3O4, Fe2O3) in 1-5 microns human serum albumin microspheres. Magnetite albumin microspheres (MAM) target almost exclusively to the reticuloendothelial system after IV administration, are stable in vitro and in vivo, and possess a long shelf life. The agent has a large magnetic susceptibility effect that selectively reduces T2 with little effect on T1. Biodistribution studies that use a dose of 20 mg MAM/kg show prompt clearance from the blood pool with marked decrease in T2 for rat liver (40%) and spleen (45%) with a small decrease in liver (5%) and spleen (10%) T1 values. Pulmonary T1 and T2 decrease transiently over the first 24 hr, while no significant changes were observed in other tissues. Imaging of a rabbit VX2 tumor model resulted in a 200% increase in the contrast ratio of VX2 tumor to normal liver on T2-weighted and mixed T1-/T2-weighted pulse sequences after administration of contrast agent. The extreme potency, excellent targeting, and apparent lack of toxicity of this agent suggest that MAM probably will have a clinical application in detecting focal hepatic and splenic lesions.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Roentgen Ray Society.